McKesson (NYSE:MCK) Releases FY 2025 Earnings Guidance

McKesson (NYSE:MCK) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 31.750-32.550 for the period, compared to the consensus earnings per share estimate of 32.190. The company issued revenue guidance of -.

McKesson Price Performance

Shares of NYSE MCK opened at $479.05 on Friday. McKesson has a 1 year low of $431.35 and a 1 year high of $637.51. The firm has a 50-day moving average of $554.66 and a 200 day moving average of $556.20. The stock has a market cap of $62.12 billion, a P/E ratio of 21.41, a price-to-earnings-growth ratio of 1.18 and a beta of 0.44.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, August 7th. The company reported $7.88 EPS for the quarter, topping the consensus estimate of $7.21 by $0.67. McKesson had a negative return on equity of 242.57% and a net margin of 0.94%. The business had revenue of $79.28 billion for the quarter, compared to the consensus estimate of $82.53 billion. During the same period in the previous year, the company posted $7.27 earnings per share. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. Research analysts expect that McKesson will post 32.07 earnings per share for the current fiscal year.

McKesson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 1st. Stockholders of record on Monday, September 2nd will be issued a dividend of $0.71 per share. This is a boost from McKesson’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, August 30th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.59%. McKesson’s dividend payout ratio is presently 12.69%.

Analyst Upgrades and Downgrades

Several brokerages have commented on MCK. Wells Fargo & Company cut their target price on McKesson from $576.00 to $535.00 and set an equal weight rating on the stock in a research note on Friday, September 13th. Leerink Partners dropped their price objective on McKesson from $670.00 to $665.00 and set an outperform rating on the stock in a research report on Thursday, September 5th. Argus lifted their price objective on McKesson from $570.00 to $670.00 and gave the stock a buy rating in a report on Monday, June 24th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of McKesson from $623.00 to $579.00 and set a buy rating on the stock in a research note on Wednesday. Finally, Mizuho lifted their price target on shares of McKesson from $540.00 to $570.00 and gave the stock a neutral rating in a research note on Thursday, August 8th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $613.36.

Insider Transactions at McKesson

In related news, CEO Brian S. Tyler sold 3,753 shares of the stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $626.03, for a total value of $2,349,490.59. Following the completion of the sale, the chief executive officer now directly owns 82,339 shares of the company’s stock, valued at approximately $51,546,684.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 11,259 shares of company stock worth $6,635,492 in the last three months. Corporate insiders own 0.11% of the company’s stock.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.